BIAF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the data provided, bioAffinity Technologies Inc (BIAF) is not a strong buy for a beginner, long-term investor at this time. While the company has shown strong sales growth for its CyPath Lung test, the recent financial performance, lack of trading signals, and technical indicators suggest a neutral stance. The investor may consider monitoring the stock for better entry points or clearer positive signals.
The MACD histogram is positive at 0.054 but contracting, indicating weakening momentum. RSI is neutral at 57.516, and moving averages are converging, suggesting no clear trend. The stock is trading below the pivot level of 3.977, with key support at 2.919 and resistance at 5.035. Overall, the technical indicators do not provide a strong buy signal.
The company reported a 146% YoY increase in unit sales of its CyPath Lung test in Q1 2026, exceeding market expectations. Additionally, the CyPath product is projected to achieve a 100% sales increase by 2026, which contributed to a 233% stock surge in March.
The company's financials for Q4 2025 showed a 27.85% YoY revenue decline and an EPS drop of 88.37% YoY, despite a slight improvement in net income. The stock has also experienced consistent price declines in pre-market, regular, and post-market trading, with no significant hedge fund or insider activity.
In Q4 2025, revenue dropped by 27.85% YoY to $1,592,813. Net income improved slightly but remained negative at -$3,137,466, up 5.75% YoY. EPS dropped significantly by 88.37% YoY to -0.7. Gross margin increased to 35.72%, up 60.32% YoY, indicating some improvement in operational efficiency.
No analyst rating or price target changes were provided. Wall Street sentiment appears neutral, with no strong pros or cons highlighted.
